Tulisokibart clinical trials
Also written MK-7240 and PRA023.
How each study uses tulisokibart is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the tulisokibart studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
17 studies that test it; most in 2024 (4)
| Year | Studies |
|---|---|
| 2020 | 1 |
| 2021 | 2 |
| 2022 | 2 |
| 2023 | 1 |
| 2024 | 4 |
| 2025 | 3 |
| 2026 | 4 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 17 · Other 0
Merck Sharp & Dohme LLC (12) · Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (5)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2
Studies that test tulisokibart.
- Feb 2027Study to Evaluate Tulisokibart in Adults With Psoriatic Arthritis (MK-7240-015)Phase 2 · Merck Sharp & Dohme LLC
- Mar 2027A Clinical Study of Tulisokibart (MK-7240) to Treat Radiographic Axial Spondyloarthritis (MK-7240-013)Phase 2 · Merck Sharp & Dohme LLC
Studies
Open first, then newest update. How each study uses tulisokibart is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 17
- A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)RecruitingPhase 3Merck Sharp & Dohme LLCNCT06430801Written as IV Tulisokibart
- A Clinical Trial Of Tulisokibart In Participants With Active, Non-Infectious Uveitis (MK-7240-019)RecruitingPhase 2Merck Sharp & Dohme LLCNCT07861074Written as Tulisokibart
- A Clinical Trial of Tulisokibart (MK-7240) in Participants With Pulmonary Sarcoidosis (MK-7240-016)RecruitingPhase 2Merck Sharp & Dohme LLCNCT07867938Written as Tulisokibart
- Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)RecruitingPhase 3Merck Sharp & Dohme LLCNCT06651281Written as Tulisokibart
- A Clinical Study of Tulisokibart (MK-7240) to Treat Radiographic Axial Spondyloarthritis (MK-7240-013)Active, not recruitingPhase 2Merck Sharp & Dohme LLCNCT07133633Written as Tulisokibart
- A Study of MK-7240 in Healthy Participants (MK-7240-009)CompletedPhase 1Merck Sharp & Dohme LLCNCT07405177Written as Tulisokibart Form 1
- Study to Evaluate Tulisokibart in Adults With Psoriatic Arthritis (MK-7240-015)Active, not recruitingPhase 2Merck Sharp & Dohme LLCNCT07486960Written as Tulisokibart
- Study to Evaluate Tulisokibart for Hidradenitis Suppurativa (MK-7240-012)Active, not recruitingPhase 2Merck Sharp & Dohme LLCNCT06956235Written as Tulisokibart
- A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)Active, not recruitingPhase 3Merck Sharp & Dohme LLCNCT06052059Written as IV Tulisokibart
- A Clinical Study of Tulisokibart (MK-7240) to Treat Rheumatoid Arthritis (RA) (MK-7240-014)Active, not recruitingPhase 2Merck Sharp & Dohme LLCNCT07176390Written as Tulisokibart
- Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)Active, not recruitingPhase 2Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)NCT05270668Written as Tulisokibart
- A Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Moderately to Severely Active Ulcerative Colitis (MK-7240-005)CompletedPhase 2Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)NCT04996797Written as Tulisokibart
- A Phase 2a Safety and Efficacy Open-Label Study of Tulisokibart (MK-7240/PRA023) in Participants With Moderately to Severely Active Crohn's Disease (MK-7240-006)CompletedPhase 2Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)NCT05013905Written as Tulisokibart
- Pharmacokinetic (PK) Characterization of Subcutaneous Tulisokibart (MK-7240-010)CompletedPhase 1Merck Sharp & Dohme LLCNCT06575595Written as Tulisokibart
- Single Dose Study of Tulisokibart (MK-7240) in Healthy Chinese Participants (MK-7240-002)CompletedPhase 1Merck Sharp & Dohme LLCNCT06829225Written as Tulisokibart
- A Study of PRA023 in Healthy VolunteersCompletedPhase 1Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)NCT04676178Written as PRA023
- Bioavailability of SC Formulation and Japanese Ethnobridging Study for PRA023CompletedPhase 1Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)NCT05354349Written as PRA023 IV Low Dose
What changed recently
From the registry's own updates since Oct 18, 2026.
Started recruiting2
Codes
What other systems call tulisokibart · ClinicalTrials.gg INT017484
- UNII (FDA) ON09TCS5H3TULISOKIBARTOne source FDA
- NCI Thesaurus C190474TulisokibartOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | ON09TCS5H3 | TULISOKIBART | One source FDA |
| NCI Thesaurus | C190474 | Tulisokibart | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.